Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer J-P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. AJP. 2003;160(2):290-6. DOI: 10.1176/appi.ajp.160.2.290. PubMed PMID: 12562575.

Metabolic risk during antipsychotic treatment.

Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004;26(12):1936-46. DOI: 10.1016/j.clinthera.2004.12.003. PubMed PMID: 15823759.

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.

Lafeuille M-H, Laliberté-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. Bmc Psychiatrybmc Psychiatry. 2013;13:221. DOI: 10.1186/1471-244X-13-221. PubMed PMID: 24016390; PubMed Central PMCID: PMC3847215.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). European Psychiatry. 2009;24(5):287-96. DOI: 10.1016/j.eurpsy.2008.12.002. PubMed PMID: 19195847.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-78. DOI: 10.3109/15622975.2012.696143. PubMed PMID: 22834451.

Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.

Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 2010;71 Suppl 2:20-6. DOI: 10.4088/JCP.9096su1cc.04. PubMed PMID: 21190649.

Self-reported life satisfaction and treatment factors in patients with schizophrenia, major depression and anxiety disorder.

Koivumaa-Honkanen HT, Honkanen R, Antikainen R, Hintikka J, Viinamäki H. Self-reported life satisfaction and treatment factors in patients with schizophrenia, major depression and anxiety disorder. Acta Psychiatr Scand. 1999;99(5):377-84. PubMed PMID: 10353454.

Correlates of life satisfaction among psychiatric patients.

Koivumaa-Honkanen HT, Viinamäki H, Honkanen R, Tanskanen A, Antikainen R, Niskanen L, et al.. Correlates of life satisfaction among psychiatric patients. Acta Psychiatr Scand. 1996;94(5):372-8. PubMed PMID: 9124086.

Vitamin supplementation in the treatment of schizophrenia.

Brown HE, Roffman JL. Vitamin supplementation in the treatment of schizophrenia. CNS Drugs. 2014;28(7):611-22. DOI: 10.1007/s40263-014-0172-4. PubMed PMID: 24846474; PubMed Central PMCID: PMC4083629.

Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia.

Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. Jama Psychiatry. 2013;70(5):481-9. DOI: 10.1001/jamapsychiatry.2013.900. PubMed PMID: 23467813; PubMed Central PMCID: PMC4394629.